Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02SSG
|
||||
| Former ID |
DNC007911
|
||||
| Drug Name |
KYS-05077
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C33H41N5O
|
||||
| Canonical SMILES |
CN(CCCCCN1CCCC1)C2=NC3=CC=CC=C3C(N2C4=CC=CC=C4)CC(=O)NC<br />C5=CC=CC=C5
|
||||
| InChI |
1S/C33H41N5O/c1-36(21-11-4-12-22-37-23-13-14-24-37)33-35-30-20-10-9-19-29(30)31(38(33)28-17-7-3-8-18-28)25-32(39)34-26-27-15-5-2-6-16-27/h2-3,5-10,15-20,31H,4,11-14,21-26H2,1H3,(H,34,39)
|
||||
| InChIKey |
DKHAGFIMNLTLHC-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Voltage-dependent T-type calcium channel alpha-1G subunit | Target Info | Inhibitor | [1] | |
| Voltage-dependent T-type calcium channel subunit alpha-1H | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | MAPK signaling pathway | ||||
| Calcium signaling pathway | |||||
| Circadian entrainment | |||||
| Type II diabetes mellitushsa04010:MAPK signaling pathway | |||||
| PANTHER Pathway | Endogenous cannabinoid signaling | ||||
| GABA-B receptor II signaling | |||||
| Nicotine pharmacodynamics pathway | |||||
| Pathway Interaction Database | Regulation of nuclear beta catenin signaling and target gene transcription | ||||
| PathWhiz Pathway | Muscle/Heart ContractionPW000564:Muscle/Heart Contraction | ||||
| Reactome | NCAM1 interactionsR-HSA-419037:NCAM1 interactions | ||||
| WikiPathways | NCAM signaling for neurite out-growth | ||||
| Nicotine Activity on Chromaffin CellsWP2355:Corticotropin-releasing hormone | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5. Epub 2006 Oct 12.Synthesis and biological evaluation of novel T-type calcium channel blockers. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.